Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of medicinal chemistry"
DOI: 10.2139/ssrn.4126049
Abstract: In the last four decades, treatment of oestrogen receptor positive (ER+) breast cancer (BCa), has focused on targeting the estrogenic receptor signaling pathway. This signaling function is pivotal to sustain cell proliferation. Tamoxifen, a competitive… read more here.
Keywords: oestrogen receptor; oestrogen; protacs; based hydroxytamoxifen ... See more keywords